What is better than Rapamycin?

  1. Everolimus, Novartis developed Everolimus to compete against rapamycin. It is almost identical to rapamycin, but different enough so that they could patent it and sell it in competition with rapamycin (Pfizer Rapamune). It has not been proven or used in life extension studies. It is already approved for the treatment of several types of cancer, and it is being investigated for other diseases such as Alzheimer's disease and Parkinson's disease. It is about 7% more bioavailable which could account for extra potency and it has a shorter half life. RAD001. Sirolimus is the preferred as it does not inhibit mTORC2 to the same extent as Everolimus.
  2. TORKinibs are a new class of mTORC1 inhibitors that work by directly targeting the mTOR kinase. TORKinibs are more potent and selective than rapamycin, and they have been shown to be effective in preclinical models of cancer and other diseases.
  3. Rheb inhibitors block the activity of Rheb, a protein that activates mTORC1. Rheb inhibitors are still in the early stages of development, but they have the potential to be more effective and less toxic than other mTORC1 inhibitors.

First-generation mTORC1 inhibitors

  1. Rapamycin
  2. Sirolimus
  3. Temsirolimus

Second-generation mTORC1 inhibitors

  1. Everolimus
  2. Ridaforolimus
  3. Deforolimus
  4. Torin 1
  5. Torin 2

Dual-specificity mTORC1/mTORC2 inhibitors

  1. Ku-0063794
  2. PP242
  3. MLN0128

Other mTORC1 inhibitors

  1. WYE-125132
  2. AZD8055
  3. INK128
  4. Rapalog analogs

📝 📜 ⏱️  ⬆️